HN2011001759A - Regimen de dosificacion para un agonista de los receptores de s1p - Google Patents
Regimen de dosificacion para un agonista de los receptores de s1pInfo
- Publication number
- HN2011001759A HN2011001759A HN2011001759A HN2011001759A HN2011001759A HN 2011001759 A HN2011001759 A HN 2011001759A HN 2011001759 A HN2011001759 A HN 2011001759A HN 2011001759 A HN2011001759 A HN 2011001759A HN 2011001759 A HN2011001759 A HN 2011001759A
- Authority
- HN
- Honduras
- Prior art keywords
- dosage regime
- receiver agonist
- agonist
- receiver
- dosage
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
- C07F9/10—Phosphatides, e.g. lecithin
Abstract
LOS MODULADORES O AGONISTAS DE LOS RECEPTORES DE S1P SE ADMINISTRAN SIGUIEDNO UN REGIMEN DE DOSIFICACION EN DONDE, DURANTE LOS DIAS INICIALES DEL TRATAMIENTO, LA DOSIFICACION DIARIA ES MAS BAJA QUE LA DOSIFICACION DIARIA CONVENCIONAL.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13967208P | 2008-12-22 | 2008-12-22 | |
US21853009P | 2009-06-19 | 2009-06-19 | |
US24671509P | 2009-09-29 | 2009-09-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
HN2011001759A true HN2011001759A (es) | 2013-11-26 |
Family
ID=41667217
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HN2011001759A HN2011001759A (es) | 2008-12-22 | 2011-06-22 | Regimen de dosificacion para un agonista de los receptores de s1p |
Country Status (40)
Country | Link |
---|---|
US (11) | US20100160259A1 (es) |
EP (7) | EP2907511A1 (es) |
JP (6) | JP2012513401A (es) |
KR (1) | KR101347919B1 (es) |
CN (1) | CN102264359A (es) |
AR (1) | AR074826A1 (es) |
AU (1) | AU2009330176C9 (es) |
BR (1) | BRPI0923500A2 (es) |
CA (1) | CA2747802C (es) |
CL (2) | CL2011001529A1 (es) |
CO (1) | CO6390117A2 (es) |
CR (1) | CR20110274A (es) |
CU (1) | CU20110136A7 (es) |
CY (4) | CY1116990T1 (es) |
DK (3) | DK3409274T3 (es) |
EA (1) | EA201100978A1 (es) |
EC (1) | ECSP11011222A (es) |
ES (3) | ES2810823T3 (es) |
FR (1) | FR20C1060I1 (es) |
HN (1) | HN2011001759A (es) |
HR (3) | HRP20151190T1 (es) |
HU (4) | HUE048717T4 (es) |
IL (3) | IL213170A0 (es) |
LT (3) | LT3409274T (es) |
MA (1) | MA32981B1 (es) |
ME (2) | ME03594B (es) |
MX (2) | MX2011006623A (es) |
NO (1) | NO2020038I1 (es) |
NZ (1) | NZ593065A (es) |
PE (1) | PE20120337A1 (es) |
PL (3) | PL2379067T3 (es) |
PT (3) | PT2379067E (es) |
RS (2) | RS59857B1 (es) |
SG (1) | SG171404A1 (es) |
SI (3) | SI2379067T1 (es) |
TN (1) | TN2011000272A1 (es) |
TW (1) | TW201028143A (es) |
UY (1) | UY32352A (es) |
WO (1) | WO2010075239A1 (es) |
ZA (2) | ZA201103863B (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4846063B2 (ja) | 2008-03-17 | 2011-12-28 | アクテリオン ファーマシューティカルズ リミテッド | 選択的s1p1レセプターアゴニストの投与法 |
ES2810823T3 (es) | 2008-12-22 | 2021-03-09 | Novartis Ag | Régimen de dosificación para un agonista del receptor S1P |
MX2012003740A (es) | 2009-09-29 | 2012-04-30 | Novartis Ag | Regimen de dosificacion de un modulador del receptor s1p. |
US20110124605A1 (en) * | 2009-11-20 | 2011-05-26 | Shreeram Aradhye | Use of an S1P Receptor Agonist |
CN108558740B (zh) | 2010-01-27 | 2021-10-19 | 艾尼纳制药公司 | S1p1受体调节剂及其盐的制备方法 |
AU2011249789B2 (en) * | 2010-05-06 | 2015-03-19 | Novartis Ag | Dosage regimen of diaryl sulfide derivatives |
EP2455080A1 (en) * | 2010-11-23 | 2012-05-23 | Almirall, S.A. | S1P1 receptor agonists for use in the treatment of multiple sclerosis |
FR2968556B1 (fr) | 2010-12-13 | 2013-12-27 | Centre Nat Rech Scient | Inhibiteurs des infections a vih et leurs utilisations |
ES2716865T3 (es) | 2011-02-18 | 2019-06-17 | Scripps Research Inst | Diferenciación dirigida de células precursoras de oligodendrocitos a un destino celular mielinizante |
AR085749A1 (es) | 2011-04-01 | 2013-10-23 | Novartis Ag | Formulaciones |
US9592268B2 (en) | 2011-05-23 | 2017-03-14 | Cornell University | Endothelium protective materials and methods of use |
TW201320994A (zh) | 2011-10-11 | 2013-06-01 | Novartis Ag | 投藥療程 |
HUE050733T2 (hu) | 2012-08-17 | 2021-01-28 | Actelion Pharmaceuticals Ltd | Eljárás (2Z,5Z)-5-(3-klór-4-((R)-2,3-dihidroxipropoxi)benzilidén)-2-(pro-pilimino)-3-(O-tolil)tiazolidin-4-on elõállítására és ezen eljárásban alkalmazott köztitermék |
IL281376B (en) * | 2013-03-06 | 2022-08-01 | Acorda Therapeutics Inc | Medicinal peptides of neuregulin for the treatment or prevention of heart failure |
WO2015053879A1 (en) | 2013-10-11 | 2015-04-16 | Teikoku Pharma Usa, Inc. | Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same |
KR101820330B1 (ko) | 2013-10-11 | 2018-01-19 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 국소 스핑고신-1-포스페이트 수용체 효현제 제형 및 이의 사용 방법 |
EP3129020A1 (en) * | 2014-04-10 | 2017-02-15 | Novartis AG | S1p modulator immediate release dosage regimen |
LT3256125T (lt) | 2014-12-11 | 2022-04-11 | Actelion Pharmaceuticals Ltd | Ponezimodo, selektyviojo s1p1 receptorių agonisto, dozavimo režimas |
KR20230151072A (ko) * | 2015-01-06 | 2023-10-31 | 아레나 파마슈티칼스, 인크. | S1p1 수용체와 관련된 상태의 치료 방법 |
US20180042895A1 (en) | 2015-02-26 | 2018-02-15 | Novartis Ag | Treatment of autoimmune disease in a patient receiving additionally a beta-blocker |
CA3002551A1 (en) | 2015-06-22 | 2016-12-29 | Arena Pharmaceuticals, Inc. | Crystalline l-arginine salt of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid(com pound 1)for use in s1p1 receptor-associated disorders |
MA47504A (fr) | 2017-02-16 | 2019-12-25 | Arena Pharm Inc | Composés et méthodes de traitement de l'angiocholite biliaire primitive |
CN110545848A (zh) | 2017-02-16 | 2019-12-06 | 艾尼纳制药公司 | 用于治疗具有肠外表现的炎症性肠病的化合物和方法 |
JP2023501217A (ja) | 2019-10-31 | 2023-01-18 | イドーシア ファーマシューティカルズ リミテッド | Cxcr7アンタゴニストのs1p1受容体調節剤との合剤 |
WO2021158848A1 (en) * | 2020-02-07 | 2021-08-12 | Argentum Pharmaceuticals Llc | Dosage regimen of an s1p receptor agonist |
WO2021158838A1 (en) | 2020-02-07 | 2021-08-12 | Argentum Pharmaceuticals Llc | Dosage regimen of an s1p receptor modulator |
CN113332435B (zh) * | 2021-06-18 | 2022-10-18 | 广州中医药大学(广州中医药研究院) | 鞘氨醇-1-磷酸4受体激动剂及其与真武汤联合在制备治疗慢性肾小球肾炎药物中的应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE122011100012I1 (de) | 1992-10-21 | 2011-10-20 | Mitsubishi Tanabe Pharma Corp | 2-Amino-1, 3-propandiolverbindung und immunosuppressium. |
CA2421893A1 (en) | 2000-08-31 | 2002-03-07 | Merck And Co., Inc. | Phosphate derivatives as immunoregulatory agents |
DE60324416D1 (de) | 2002-05-16 | 2008-12-11 | Novartis Ag | Verwendung von edg rezeptor bindenden wirkstoffen für die krebstherapie |
WO2005025553A2 (en) * | 2003-09-12 | 2005-03-24 | Neuronova Ab | Treatment of disorders of nervous systemsystem with fty720 |
US20060002999A1 (en) * | 2004-06-17 | 2006-01-05 | Forest Laboratories, Inc. | Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane |
RU2478384C2 (ru) * | 2004-11-29 | 2013-04-10 | Новартис Аг | Курс лечения с использованием агониста рецептора s1p |
EP1688141A1 (en) * | 2005-01-31 | 2006-08-09 | elbion AG | The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome |
EP1850689A4 (en) * | 2005-02-10 | 2013-05-22 | G I View Ltd | TECHNIQUES FOR DISPLACING A GASTROINTESTINAL TOOL EQUIPPED WITH A GUIDING ELEMENT |
CN101820916A (zh) * | 2007-10-12 | 2010-09-01 | 诺瓦提斯公司 | 包含鞘氨醇1磷酸(s1p)受体调节剂的组合物 |
JP4846063B2 (ja) * | 2008-03-17 | 2011-12-28 | アクテリオン ファーマシューティカルズ リミテッド | 選択的s1p1レセプターアゴニストの投与法 |
CN104800196A (zh) * | 2008-06-20 | 2015-07-29 | 诺华股份有限公司 | 用于治疗多发性硬化的儿科组合物 |
ES2810823T3 (es) | 2008-12-22 | 2021-03-09 | Novartis Ag | Régimen de dosificación para un agonista del receptor S1P |
MX2011006625A (es) * | 2008-12-22 | 2011-09-28 | Novartis Ag | Regimen de dosificacion de un agonista de los receptores de s1p. |
-
2009
- 2009-12-21 ES ES18201062T patent/ES2810823T3/es active Active
- 2009-12-21 NZ NZ593065A patent/NZ593065A/xx not_active IP Right Cessation
- 2009-12-21 SG SG2011037629A patent/SG171404A1/en unknown
- 2009-12-21 WO PCT/US2009/068888 patent/WO2010075239A1/en active Application Filing
- 2009-12-21 HU HUE18179301A patent/HUE048717T4/hu unknown
- 2009-12-21 PL PL09797234T patent/PL2379067T3/pl unknown
- 2009-12-21 MA MA34034A patent/MA32981B1/fr unknown
- 2009-12-21 SI SI200931311T patent/SI2379067T1/sl unknown
- 2009-12-21 US US12/642,892 patent/US20100160259A1/en not_active Abandoned
- 2009-12-21 EP EP15158251.7A patent/EP2907511A1/en not_active Withdrawn
- 2009-12-21 MX MX2011006623A patent/MX2011006623A/es unknown
- 2009-12-21 LT LTEP18179301.9T patent/LT3409274T/lt unknown
- 2009-12-21 LT LTEP18201062.9T patent/LT3453387T/lt unknown
- 2009-12-21 EP EP09797234.3A patent/EP2379067B1/en not_active Revoked
- 2009-12-21 ME MEP-2019-339A patent/ME03594B/me unknown
- 2009-12-21 ES ES18179301T patent/ES2760607T3/es active Active
- 2009-12-21 EP EP22187007.4A patent/EP4098256A1/en active Pending
- 2009-12-21 AU AU2009330176A patent/AU2009330176C9/en not_active Withdrawn - After Issue
- 2009-12-21 RS RS20191546A patent/RS59857B1/sr unknown
- 2009-12-21 EP EP20160225.7A patent/EP3677260A1/en active Pending
- 2009-12-21 DK DK18179301.9T patent/DK3409274T3/da active
- 2009-12-21 DK DK09797234.3T patent/DK2379067T3/en active
- 2009-12-21 SI SI200932080T patent/SI3453387T1/sl unknown
- 2009-12-21 PL PL18179301T patent/PL3409274T3/pl unknown
- 2009-12-21 KR KR1020117017073A patent/KR101347919B1/ko active IP Right Grant
- 2009-12-21 PE PE2011001265A patent/PE20120337A1/es not_active Application Discontinuation
- 2009-12-21 HU HUE18201062A patent/HUE052048T2/hu unknown
- 2009-12-21 JP JP2011542521A patent/JP2012513401A/ja not_active Withdrawn
- 2009-12-21 HU HUE09797234A patent/HUE026869T2/en unknown
- 2009-12-21 TW TW098143960A patent/TW201028143A/zh unknown
- 2009-12-21 EA EA201100978A patent/EA201100978A1/ru unknown
- 2009-12-21 ES ES09797234.3T patent/ES2552823T3/es active Active
- 2009-12-21 AR ARP090105010A patent/AR074826A1/es not_active Application Discontinuation
- 2009-12-21 PT PT97972343T patent/PT2379067E/pt unknown
- 2009-12-21 CN CN2009801518640A patent/CN102264359A/zh active Pending
- 2009-12-21 EP EP18201062.9A patent/EP3453387B1/en active Active
- 2009-12-21 PT PT182010629T patent/PT3453387T/pt unknown
- 2009-12-21 US US13/141,552 patent/US20110257133A1/en not_active Abandoned
- 2009-12-21 CA CA2747802A patent/CA2747802C/en active Active
- 2009-12-21 PL PL18201062T patent/PL3453387T3/pl unknown
- 2009-12-21 UY UY0001032352A patent/UY32352A/es not_active Application Discontinuation
- 2009-12-21 EP EP18179301.9A patent/EP3409274B1/en active Active
- 2009-12-21 RS RS20200900A patent/RS60666B1/sr unknown
- 2009-12-21 PT PT181793019T patent/PT3409274T/pt unknown
- 2009-12-21 SI SI200932015T patent/SI3409274T1/sl unknown
- 2009-12-21 EP EP16182876.9A patent/EP3120844A1/en not_active Withdrawn
- 2009-12-21 BR BRPI0923500-0A patent/BRPI0923500A2/pt not_active Application Discontinuation
- 2009-12-21 ME MEP-2020-156A patent/ME03802B/me unknown
- 2009-12-21 DK DK18201062.9T patent/DK3453387T3/da active
-
2011
- 2011-05-25 ZA ZA2011/03863A patent/ZA201103863B/en unknown
- 2011-05-25 CR CR20110274A patent/CR20110274A/es not_active Application Discontinuation
- 2011-05-26 IL IL213170A patent/IL213170A0/en unknown
- 2011-05-26 TN TN2011000272A patent/TN2011000272A1/fr unknown
- 2011-06-17 MX MX2021010759A patent/MX2021010759A/es unknown
- 2011-06-21 CL CL2011001529A patent/CL2011001529A1/es unknown
- 2011-06-22 EC EC2011011222A patent/ECSP11011222A/es unknown
- 2011-06-22 HN HN2011001759A patent/HN2011001759A/es unknown
- 2011-06-22 CU CU20110136A patent/CU20110136A7/es unknown
- 2011-06-23 CO CO11079290A patent/CO6390117A2/es not_active Application Discontinuation
-
2012
- 2012-08-06 ZA ZA2012/05942A patent/ZA201205942B/en unknown
-
2013
- 2013-05-31 CL CL2013001558A patent/CL2013001558A1/es unknown
- 2013-09-06 US US14/020,058 patent/US20140066657A1/en not_active Abandoned
-
2014
- 2014-01-31 US US14/169,660 patent/US20140148415A1/en not_active Abandoned
- 2014-04-10 JP JP2014080892A patent/JP2014144970A/ja not_active Withdrawn
-
2015
- 2015-10-14 JP JP2015202669A patent/JP2016135752A/ja not_active Withdrawn
- 2015-11-06 HR HRP20151190TT patent/HRP20151190T1/hr unknown
- 2015-11-30 CY CY20151101084T patent/CY1116990T1/el unknown
- 2015-12-02 US US14/956,855 patent/US20160081949A1/en not_active Abandoned
-
2016
- 2016-05-23 US US15/161,778 patent/US20160263061A1/en not_active Abandoned
-
2017
- 2017-03-06 JP JP2017041331A patent/JP2017141238A/ja not_active Withdrawn
- 2017-03-21 US US15/465,091 patent/US20170189353A1/en not_active Abandoned
-
2018
- 2018-06-11 US US16/005,137 patent/US20180289638A1/en not_active Abandoned
- 2018-11-26 US US16/199,905 patent/US20190091180A1/en not_active Abandoned
-
2019
- 2019-05-22 JP JP2019095899A patent/JP7329965B2/ja active Active
- 2019-12-02 HR HRP20192175TT patent/HRP20192175T1/hr unknown
- 2019-12-03 CY CY20191101264T patent/CY1122812T1/el unknown
-
2020
- 2020-05-05 US US16/867,293 patent/US20200330407A1/en not_active Abandoned
- 2020-05-18 IL IL274756A patent/IL274756A/en unknown
- 2020-07-27 HR HRP20201167TT patent/HRP20201167T1/hr unknown
- 2020-08-03 CY CY20201100712T patent/CY1123255T1/el unknown
- 2020-11-17 LT LTPA2020005C patent/LTPA2020005I1/lt unknown
- 2020-11-18 NO NO2020038C patent/NO2020038I1/no unknown
- 2020-11-19 HU HUS2000046C patent/HUS2000046I1/hu unknown
- 2020-11-19 FR FR20C1060C patent/FR20C1060I1/fr active Active
- 2020-11-19 CY CY2020036C patent/CY2020036I2/el unknown
- 2020-11-23 IL IL278914A patent/IL278914A/en unknown
-
2021
- 2021-09-20 US US17/479,649 patent/US20220142949A1/en active Pending
-
2022
- 2022-04-21 JP JP2022070231A patent/JP2022103194A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HN2011001759A (es) | Regimen de dosificacion para un agonista de los receptores de s1p | |
UY32350A (es) | Régimen de dosificación de un agonista de los receptores de s1p | |
CO6551740A2 (es) | Derivados pirazólicos como moduladores de los canales de calcio activados por la liberación de calcio | |
CL2012000921A1 (es) | Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes. | |
CR20140223A (es) | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a | |
UY35465A (es) | Nuevos compuestos como inhibidores de reorganizado durante la transfección (ret) | |
PE20150887A1 (es) | Compuestos de benceno sustituidos | |
CL2022001743A1 (es) | Dosis de gamma-hidroxibutirato (ghb) | |
PE20142371A1 (es) | Combinacion farmaceutica de 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y un antiepileptico | |
UY30572A1 (es) | N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2 | |
CL2015002608A1 (es) | Compuesto de amino-pirazol y usos medicinales relacionados. | |
NI201400112A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
CL2012002551A1 (es) | Combinacion farmaceutica que comprende por lo menos un 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol de fórmula (i) y por lo menos un antagonista de nmda; composicion farmaceutica; y uso para el tratamiento del dolor. | |
DOP2014000098A (es) | 2-tiopirimidinonas | |
UY32853A (es) | Nuevos compuestos de oxadiazol | |
BR112015030515A2 (pt) | intensificadores de inibidores de homólogo 2 de zeste | |
CO6351779A2 (es) | Inhibidores de molecula pequeña de la activacion n-terminal del receptor de androgenos | |
DOP2013000304A (es) | Moduladores alostéricos positivos del receptor de acetilcolina nicotínico | |
CL2021002946A1 (es) | Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1 | |
CL2009001139A1 (es) | Composicion que comprende un lisofosfolipido para tratar los efectos de la inflamacion. | |
CO6670518A2 (es) | Tratamiento de infecciones de clostridium difícile en pacientes bajo terapia con antibióticos | |
CL2009001018A1 (es) | Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia, teniendo los pacientes un incremento del nivel de creatinina debido a la utilizacion de dronedarona. | |
ECSP14013158A (es) | Moduladores alostéricos positivos del receptor de acetilcolina nicotínico | |
CU20130155A7 (es) | Régimen de dosificación para un agonista de los receptores de s1p | |
ECSP13012983A (es) | Nuevos acidos piperidinil-monocarboxilicos como agonistas del receptor de esfingosina-1-fosfato-1(s1p1) |